Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Mergers Have Defined Healthcare in Recent Years, but They Aren’t the Only Way Forward

Merger announcements have dominated recent news in healthcare. In 2018, Advocate Health Care merged with Aurora Health Care to form Advocate Aurora Health, one of the largest not-for-profit systems in the country. But that merger only took place after Advocate spent two and a half years and $15 million on a failed attempt to unite…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Merger announcements have dominated recent news in healthcare. In 2018, Advocate Health Care merged with Aurora Health Care to form Advocate Aurora Health, one of the largest not-for-profit systems in the country. But that merger only took place after Advocate spent two and a half years and $15 million on a failed attempt to unite with NorthShore University HealthSystem.[1] And Catholic Health Initiatives and Dignity Health recently merged to create CommonSpirit Health after more than two years of challenging negotiations.[2] However, recent developments show that a merger is not always the way to go. Rumors circulated for months that St. Louis-based Ascension Health was considering a merger with Renton, Washington’s Providence St. Joseph Health, to create the nation’s largest system of hospitals. But the two health systems ultimately decided to shelve talks, opting to restructure their organizations instead.[3]

A particularly striking example of a merger exploration that ended before completion is that between Baylor Scott & White Health and Memorial Hermann Health System. The systems recently announced they had dissolved their consolidation plan after previously signing a letter of intent and conducting months of talks.[4] The deal would have combined two of the most well-known hospital systems in Texas to create the largest nonprofit integrated delivery system in the state, and possibly the southwest.[5] In a joint statement the two hospital systems said, “Ultimately, we have concluded that as strong, successful organizations, we are capable of achieving our visions for the future without merging at this time,” adding, “We will continue to seek opportunities for collaboration as two forward-thinking, mission-driven organizations.”[6] Ultimately, consolidation is the right move for some organizations, but many independent hospitals simply don’t want to be acquired or take part in a major merger.

As stated in our previous post, by design, stand-alone hospitals differ significantly from their larger counterparts. They value their independence, flexibility, and freedom from corporate mandates or value extraction that could ultimately detract from care. They are fixtures in their communities and have formed generational relationships with the patients they serve. They pride themselves on their agility and aptitude to bypass large-system bureaucracy.[7] Though there are undeniable strengths to remaining independent, there are just as many challenges. One of them is size and scale, which puts smaller hospitals in a difficult position when negotiating with insurers and suppliers. Often, they don’t have the perceived stature of larger systems to command the desired results. Mergers are one way to build scale, but it isn’t the only way. TPC offers an alternative that allows hospitals to remain independent while gaining the benefits of economies of scale and the shared knowledge of a larger system.

TPC creates a virtual system of independent, community-based hospitals that together achieve sizable tangible value that lowers costs and enables Members to remain competitive. By way of standardization and performance optimization at the financial, operational, and clinical levels, TPC builds a framework for hospitals to remain independent but take advantage of their collective size to achieve similar results to national systems. This approach allows stand-alone hospitals to remain agile, while also providing access to the resources and benefits that only large scales allow. It’s the perfect solution for hospitals disinterested in merging, but wary of remaining isolated in an industry undergoing major change.

Stronger Together. Superior Results. To learn more about the TPC and their vision for healthcare, just visit: http://www.tpc1.com/who-we-are/

[1] https://www.chicagotribune.com/business/ct-biz-advocate-aurora-merger-done-20180403-story.html

[2] https://www.modernhealthcare.com/article/20190201/NEWS/190209994

[3] https://www.bizjournals.com/seattle/news/2018/03/29/providence-st-joseph-ascension-merger-on-hold.html

[4] https://www.healthexec.com/topics/healthcare-economics/baylor-scott-white-memorial-hermann-wont-merge

[5] https://www.healthleadersmedia.com/strategy/baylor-health-care-system-scott-white-merge

[6] https://www.bizjournals.com/dallas/news/2019/02/05/merger-called-off-between-baylor-scott-white.html

[7] https://www.beckershospitalreview.com/hospital-transactions-and-valuation/to-merge-or-not-to-merge-benefits-challenges-and-the-future-for-stand-alone-hospitals.html

0 Likes

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512